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ABSTRACT
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. 
Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome 
exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo 
chronic pharmacological treatments that could alter disease initiation, progression 
and therapy response. Here we show that treatment with anti-cholesterolemic 
drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity 
of obesogenic diets. In addition, the use of a mouse model of prostate cancer and 
human prostate cancer xenografts revealed that in vivo simvastatin administration 
alone increases prostate cancer aggressiveness. In vitro cell line systems supported 
the notion that this phenomenon occurs, at least in part, through the direct action on 
cancer cells of low doses of statins, in range of what is observed in human plasma. In 
sum, our results reveal a prostate cancer experimental system where statins exhibit 
an undesirable effect, and warrant further research to address the relevance and 
implications of this observation in human prostate cancer.
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INTRODUCTION
The initiation, progression and therapeutic 
eradication of cancer is largely associated to the evolving 
mutational landscape of the tumor [1]. However, tissue-
specific factors, the tumor microenvironment and the 
immune activation status are determinant factors of 
cancer cell survival and progression [2]. Critically, 
systemic metabolic alterations, nutrition, obesity and 
comorbidity-derived long-term therapies in elderly 
population shape the incidence and aggressiveness 
of cancer in our society [3-6]. Prostate cancer (PCa) is 
among the most frequent tumor type in men, and the 
main risk factors include family history, race and age 
[7]. Importantly, due to its predominant diagnosis in men 
above 60 years old, comorbidities are frequent. These 
include obesity, metabolic syndrome, arterial hypertension 
and diabetes [8]. In turn, PCa patients at the time of 
diagnosis are commonly subject to chronic therapies. 
Anti-hypercholesterolemic treatment is prescribed to 
millions of individuals around the globe in the form of 
statins, and their benefits and harms have been studied 
[9]. Due to their extensive and chronic use, it is of the 
utmost importance to carefully evaluate the impact of this 
long-term therapy on the biology of cancer, at doses and 
administration modes achieved in human subjects. In this 
study, we evaluated the impact of statin treatment in the 
pathogenesis and progression of PCa. Through the use of 
PCa mouse models, cellular systems and observational 
studies in patients we demonstrate that treatment with 
these compounds is associated to increased aggressive 
features in this disease.
RESULTS
Anti-hypercholesterolemic treatments are often 
prescribed in the context of overweight or obesity [16]. 
Therefore, in order to evaluate the impact of statins (the 
main family of anticholesterolemic compounds, inhibitors 
of the mevalonate pathway enzyme Hydroxymethyl 
glutaryl CoA reductase - HMGCR) in PCa biology, 
we first evaluated the effect of statin exposure in the 
context of obesity in Pten prostate-specific heterozygous 
mice (Ptenpc+/-), which exhibit a weak, non-cancerous 
phenotype [10, 17]. We focused on the predominant statin 
used in the clinic, simvastatin. It is worth noting that the 
hydrophilic nature differs among statins, which could 
lead to distinct biological consequences in vivo [18]. We 
queried the available bibliography (Supplementary Table 
1) and determined a low dose of simvastatin with proven 
biological activity [19]. Simvastatin was loaded in food 
pellets and provided ad libitum, thus enabling the uptake of 
simvastatin in an administration mode and concentration 
comparable to human subjects, including the activation of 
the drug in the liver [20]. We established an experimental 
design in which we induced obesity by feeding the mice 
with western diet (containing high fat and carbohydrates) 
[21], and once the obesity was achieved, simvastatin was 
loaded to the obesogenic diet (Figure 1a for experimental 
design). At the end of the experiment, the weight of the 
mice on western diet was significantly increased compared 
to mice on standard diet (45.44 ± 1.34 gr versus 40.72 
± 2.15 gr, p = 0.04), whereas simvastatin addition to 
western diet did not have an impact on this parameter 
(46.83 ± 1.05 gr, p = 0.43). The combination of obesity 
and statin treatment increased prostate mass (Figure 1b). 
At the histological level, obese Ptenpc+/- mice exhibited 
50% incidence of prostate intraepithelial neoplasia (PIN) 
at 11 months of age, without the appearance of invasive 
carcinoma lesions (Figure 1c, d). Strikingly, simvastatin 
treatment administered after the onset of obesity (Figure 
1a) led to invasive cancerous lesions with an incidence 
of 45%, a phenotype only achieved in this mouse model 
when both copies of Pten are lost in the prostate epithelium 
[10, 13] (Figure 1c, 1d). Molecular analysis of these 
prostates revealed that simvastatin treatment exacerbated 
cell proliferation, accounted by Ki67 positivity (Figure 
1d, 1e). These results provide unprecedented evidence for 
an undesired consequence of the treatment with statins in 
obese individuals with genetic predisposition to develop 
PCa.
We next evaluated the impact of statin treatment 
on PCa initiation using a Pten prostate-specific knockout 
(Ptenpc-/-), which allows the study of proliferative burst 
under oncogenic signalling [13, 17]. Four-week statin 
treatment in Ptenpc-/- at the time of Pten excision and 
disease onset (8 weeks of age) resulted in an increased 
prostate mass and proliferation, without overt histological 
changes (Figure 2). 
PCa initiation, progression and resistance to therapy 
depend on distinct molecular mechanisms. Advanced PCa 
is currently treated with androgen-deprivation therapy 
[22]. Previous reports have documented that Ptenpc-/- 
mice subject to orchiectomy exhibit overall pathological 
response [23]. Therefore, we performed surgical castration 
in order to address effects of statins on cancer cell biology 
beyond proliferation (Supplementary Figure 1a). In line 
with the undesirable effect of statin treatment observed 
in the other experimental systems, we observed a trend 
towards increased prostate mass and castration resistance 
in simvastatin-treated mice (Supplementary Figure 
1b-d), in the absence of a significant alteration in cell 
proliferation (Supplementary Figure 1d, e). 
In sum, the use of a faithful mouse model of PCa 
uncovers an unexpected effect of simvastatin that is 
associated to the increase of PCa cell proliferation, cancer 
initiation and resistance to therapy. 
Our data provides evidence of the undesirable effect 
of simvastatin in murine PCa. To extrapolate these results 
to human PCa, we took advantage of a human PCa cell 
line, PC3, and evaluated the impact of simvastatin feeding 
on tumor growth in subcutaneous xenografts. In line 
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with our previous results, simvastatin fed mice exhibited 
significantly heightened tumor growth rate (Figure 3a). 
Multiple reports have documented the antitumoral 
effect of statins in vitro. The majority of these studies 
rely on doses of these compounds in the micromolar 
range [24-45] (Supplementary Table 2). However, the 
concentration of statins found in plasma of patients 
subject to anti-cholesterolemic treatments is in the 
nM range [46]. Therefore, we sought to establish an in 
vitro experimental model that would recapitulate the 
concentration of statins achieved in patients. To this 
end, we first corroborated the reported effects of high 
simvastatin doses. Micromolar doses of simvastatin 
elicited an anti-proliferative and cytotoxic response in PCa 
cells (Supplementary Table 2; Supplementary Figure 2a, 
b). Next, we designed an experimental approach aimed at 
ascertaining the cell autonomous biological consequences 
of low simvastatin doses in PCa cells. We pre-treated 
PC3 cells with 50 nM simvastatin for a minimum of 7 
days, which did not result in any sign of toxicity in two-
dimensional growth assays (Figure 3b, Supplementary 
Figure 2c). This treatment schedule did not affect cell 
migration (Supplementary Figure 2d), but surprisingly 
resulted in elevated self-renewal capacity and anchorage-
independent growth (Figure 3c, 3d). Of note, the effect of 
simvastatin in vitro was recapitulated in other cell lines 
(LNCaP and 22RV1, Figure 3d) and with an alternative 
HMGCR inhibitor (fluvastatin, Supplementary Figure 
2e). Moreover, moderate genetic inhibition of HMGCR 
with two independent doxycycline-inducible shRNAs 
Figure 1: Simvastatin administration cooperates with obesogenic diets to drive prostate cancer. a. Schematic representation 
of the experimental design. 4-6 week-old prostate-specific Pten-heterozygous (Ptenpc+/-; pc+/-) mice were fed with western diet (WD) to 
induce obesity. At 6 months of age, mice were randomly assigned to WD or WD loaded with simvastatin (WD + SIM) and fed for 5 months, 
and tissues were harvested and analysed. b. Prostate lobes weights of Pten-heterozygous (Ptenpc+/-; pc+/-) mice fed with WD (n = 16) or 
WD + SIM (n = 11). VP, DLP, AP refer to ventral, dorsolateral and anterior prostates, respectively. c. Histopathological characterization 
of the prostate (Normal: no lesions; LGPIN: Low-grade prostatic intraepithelial neoplasia; HGPIN: High-grade prostatic intraepithelial 
neoplasia; Cancer: prostate adenocarcinoma) (WD, n = 16, WD+SIM, n = 11). d. Representative histological images of the prostate. Left, 
H&E (Haematoxylin-eosin) and right, Ki67 staining. WD shows non-cancerous tissue, WD+SIM shows adenocarcinoma. e. Quantification 
of Ki67 positive nuclei (%), indicating proliferating cells (WD, n = 5; WD SIM, n = 5). Statistical analysis: Mann-Whitney statistic test (b, 
e) and Chi Square test with 3 degree freedom (c). Error bars represent median with interquartile range. *p < 0.05, **p < 0.01, ***p < 0.001.
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(Supplementary Figure 2f, g) elicited an effect comparable 
to simvastatin in anchorage-independent growth. 
Conversely, subtle HMGCR over-expression elicited the 
predicted opposing effect (Supplementary Figure 2f, h). 
Since anchorage-independent growth and self-
renewal capacity are required steps in tumor re-initiation 
and metastatic seeding [47], we evaluated whether PC3 
cells treated for 7 days with 50 nM simvastatin would 
harbour elevated metastatic capacity. To this end, we 
injected PC3 cells pre-treated with vehicle or simvastatin 
in the tail vein of immunocompromised mice, and analysed 
the appearance of lung metastatic lesions (Supplementary 
Figure 2i right). Simvastatin treatment did not reduce 
metastatic burden, but rather resulted in increased rate of 
lung metastasis, which did not reach statistical significance 
(p = 0.1) probably owing to the low number of mice 
(Supplementary Figure 2i). In sum, our results support the 
existence of a biological context where statin treatment 
could promote features of PCa aggressiveness. 
The effect of statins could be associated to the 
alteration in major oncogenic signalling pathways 
sustaining PCa function. Therefore, we evaluated 
the levels and/or activity of androgen receptor (AR), 
Phosphoinositide 3-kinase (PI3K, using as a readout 
serine 473 phosphorylation of AKT) and mitogen 
activated protein kinase (MAPK, using as a readout 
tyrosine 202/204 phosphorylation of ERK - extracellular 
signal regulated kinase) in AR-expressing LNCaP (AR-
Figure 2: Simvastatin administration increases feature of aggressiveness in prostate cancer initiation. a. Schematic 
representation of the experimental design. 8 week-old Pten-deficient (Ptenpc-/-; pc-/-) mice were fed with simvastatin-loaded (SIM) diet or 
chow for four weeks, and tissues were harvested and analysed. b. Prostate lobe weights of Pten-deficient mice fed chow (pc-/- Chow, n 
= 18) and SIM diet (pc-/- SIM, n = 9). VP, DLP, AP refer to ventral, dorsolateral and anterior prostates respectively. c. Histopathological 
characterization of the prostate. (LGPIN: Low-grade prostatic intraepithelial neoplasia; HGPIN: High-grade prostatic intraepithelial 
neoplasia; Cancer: prostate adenocarcinoma) (Chow, n = 9; SIM, n = 6). d. Representative histological images of the prostate. Left, H&E 
(Haematoxylin-Eosin) and right, Ki67 staining, showing prostate intraepithelial neoplasia (PIN) in Pten-deficient mice fed with SIM or 
chow. e. Quantification of Ki67 positive nuclei (%), indicating proliferating cells, in pc-/- Chow (n = 5) and pc-/- SIM (n = 6). Statistical 
analysis: Mann-Whitney statistic test (b, e) and Chi Square test with 2 degree freedom (c). Error bars represent median with interquartile 
range. N.S.: Non-significant. *p < 0.05, **p < 0.01.
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dependent) and 22RV1 (AR-independent) cell lines. None 
of these parameters (AR protein levels or activity by 
means of the mRNA abundance of its target KLK3; AKT 
or ERK phosphorylation) was consistently altered neither 
in vitro nor in vivo, thus precluding their involvement 
as a major component of the mechanism of action of 
statins (Supplementary Figure 3; unprocessed scans in 
Supplementary Figure 5). Of note, we also monitored 
the expression of cholesterol transporters and metabolic 
enzymes that could be altered as a consequence of statin 
treatment [48, 49]. We did not observe consistent changes 
neither in low density lipoprotein receptor (LDLR) nor in 
other enzymes and transporters (Apolipoprotein (APO) 
genes, ACAT1 (acetyl CoA cholesterol acyl transferase) 
and 2 and lipoprotein lipase (LPL)), precluding a major 
involvement of such alterations in the biological effect of 
Figure 3: Low-dose simvastatin enhances features of prostate cancer aggressiveness in vitro and in vivo. a. Tumor 
growth rate from PC3 cell xenografts upon feeding nude mice with chow or simvastatin-loaded (SIM) diet. 5 mice for condition were 
used, 4 tumors per mouse. 100.000 PC3 cells were injected. Mice were fed with simvastatin loaded chow starting 72h before injections. 
Box plot representation. b. Schematic representation of simvastatin treatment in vitro in PC3 cells. Cells were pre-treated for 7 days with 
50 nM simvastatin, and biological effects were evaluated. c. Effect of simvastatin pre-treatment on clonal self-renewal capacity (n = 5) in 
PC3 cells. d, Effect of 50 nM simvastatin pre-treatment on anchorage-independent growth in PC3, 22RV1 and LNCaP cell lines. Statistical 
analysis: Mann Whitney test (a), one sample t test (c, d. Error bars represent standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001.
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these compounds (Supplementary Figure 4).
Observational studies have evaluated the 
association of statins to PCa risk and aggressiveness 
(Supplementary Table 3) [50, 51]. Our data suggests 
that there could be a subset of PCa patients where statins 
could exert undesirable effects. We analyzed data from a 
prospective study conducted in Vall d´Hebron Research 
Institute [15]. To carry out this analysis, 2408 men were 
selected, after excluding those men who were undergoing 
5-α-reductase inhibitors treatment and those men who 
had been using statins for less than three years. In this 
cohort, the impact of statins was previously evaluated as 
part of a multivariate analysis with other factors such as 
age, PSA or serum cholesterol levels; or in combination 
with plasma cholesterol or aspirin treatment [15, 40]. 
37.2% of patients passed the statin treatment criteria 
beyond 3 years. In the multivariate study, statins were 
not associated to PCa risk. PCa was detected in 848 men 
(35.2%), and 297 of them (35%) were classified as high 
grade (HGPCa, Gleason score >7; as compared to Low 
Grade PCa (LGPCa; Gleason score ≤7)). In line with 
previous reports, treatment with this family of compounds 
reduced the risk of suffering from PCa (overall risk (OR) 
= 0.717; p = 0.006). However, 41.8% of patients treated 
with statins were diagnosed with HGPCa, whereas 
aggressive disease was less prevalent among patients 
not taking the cholesterol-lowering drug (32.5% of statin 
non-treated patients presented HGPCa, p = 0.012, OR 
1.495 (1095-2.039)) (Supplementary Table 4). To which 
extent the effect of statins is a predominant selective effect 
reducing the incidence of LGPCa, or whether it has an 
activity promoting the appearance of HGPCa remains to 
be studied, since both scenarios could lead to the results 
obtained in our analysis. In addition, our observational 
study does not account for statin dose, which, according 
to our experimental data, could be an important factor. Of 
note, these results are in line with the increased risk of 
high grade cancer reported in patients subject to statins 
that show normalized serum cholesterol levels [15], or 
patients with combined treatment of statins and aspirin 
[40]. Importantly, these results were corroborated in a 
multivariate analysis with other chronic pharmacological 
treatments (Supplementary Table 5). It should be noted 
that the controversy in observational studies with statins 
remains high [52], and additional analysis in well-
annotated cohorts is granted. 
DISCUSSION
Systemic metabolic alterations impact on the 
function and cross-talk of cells in our body. Indeed, 
the incidence and aggressiveness of cancer is in part 
associated to non-cell autonomous factors, such as 
nutrition, obesity or chronic therapeutic regimes [3, 
53]. Statins are administered to millions of people 
worldwide. In turn, their consequences on tumor biology 
have become a research field of great interest. We have 
studied the consequences of statin treatment in PCa 
biology, and demonstrated through the use of a wide array 
of pre-clinical and experimental approaches that these 
compounds promote features of disease aggressiveness. 
It should be noted that our experimental systems might 
reflect the existence of a sub-population of PCa patients 
for whom statins have undesirable effects, in line with 
other studies [54, 55]. Interestingly, a large study of 47294 
individuals focused on the study of coronary heart disease 
observed that patients treated with low-dose simvastatin 
(5-10 mg/day) and achieving low total serum cholesterol, 
presented increased risk of developing cancer (OR = 
3.16 for serum cholesterol < 160; OR = 1.85 for serum 
cholesterol = 160-179) [56]. The analysis of the available 
observational studies supports the existence of a context 
where statins could increase the aggressiveness of the 
disease in PCa patients. Overall, current epidemiological 
studies [15, 40, 50, 51, 54-68] would benefit of re-analysis 
taking into account this new information. 
Experimental cancer systems often serve for the 
validation and causal demonstration of observations 
originated in patient studies. However, these approaches 
can also be employed to predict the consequences of 
societal or lifestyle changes. Our experimental systems 
provide very provocative results that still lack full clinical 
validation to demonstrate the potential existence of a 
subset of PCa patients in which statins exert an undesired 
activity. Our results warrant further analysis of the cell 
autonomous and systemic impact of statin treatment in 
PCa and other cancers in order to understand the biological 
context associated to a protective or detrimental activity of 
these compounds. 
MATERIALS AND METHODS
Cellular and molecular assays
Human prostate carcinoma cell lines (PC3, 
LNCaP and 22RV1) were purchased from Leibniz-
Institut - Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (DSMZ, Germany), who provided 
authentication certificate. In addition, we validated 
their identity by microsatellite analysis. Cell lines were 
routinely monitored for mycoplasma contamination. 
Simvastatin and mevalonate (Sigma-Aldrich) for in vitro 
purposes were activated by heating (50 ºC) with NaOH 
(0.1N) for two hours. Fluvastatin (Sigma-Aldrich) was 
used following manufacturers’ indications. 
For clonogenicity assay, PC3 cells expressing GFP 
were plated in poly-HEMA pretreated 384 plates at 1 cell 
per well in DMEM/F12 (Gibco) plus EGF (100 mg/ml), 
bFGF (10 mg/ml), B27 (Thermo Fisher), 8% BSA (Sigma-
Aldrich). Wells with 0, 1, or >1 cells were annotated. 7 
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days after plating, sphere formation from wells with 
single cells was quantified. Crystal violet-based cell 
number quantification, soft-agar anchorage independent 
growth and western blotting were performed as previously 
described [10]. Antibodies used for western blotting: 
androgen receptor (clone D6F11, Cell Signaling #5153), 
phosphorylated ERK (T202/204; extracellular signal 
regulated kinase, clone 20G11, Cell Signaling #4376), 
phosphorylated AKT (S473; clone 736E11, Cell Signaling 
#3787), ERK (clone 3A7, Cell Signalling #9107), AKT 
(Cell Signalling #9272), β-Actin (clone AC-74; Sigma 
#A5316), LDLR (EP1553Y; Abcam #ab52818) and 
HSP90 (Heat Shock Protein 90, Cell Signaling #4874). 
RNA was extracted using NucleoSpin® RNA 
isolation kit from Macherey-Nagel (ref: 740955.240C). 
For RNA harvesting from mouse tissue, we introduced 
a prior step consisting on the incubation of the tissue 
in RNAlater ICE (Thermo Fisher) overnight at -20ºC 
and phenolic extraction with TRIreagent (TR118, 
MRC). In all cases, 1μg of total RNA was used for 
cDNA synthesis using qScript cDNA Supermix from 
Quanta (ref. 95048). Quantitative Real Time PCR 
(qRTPCR) was performed as previously described [10]. 
Universal Probe Library (Roche) primers and probes 
employed in human samples: HMGCR, primers: Fw: 
gttcggtggcctctagtgag, Rv: gcattcgaaaaagtcttgacaac; 
Probe: 65. KLK3, primers: Fw: gtgcttgtggcctctcgt 
Rv: agcaagatcacgcttttgttc; Probe: 44. LDLR, primers: 
Fw: gatagtgacaatgtctcaccaagc, Rv: cctcacgctactgggcttc; 
Probe: 6. APOD, primers: Fw: gagaggccagtcaccaagac, 
Rv: gagaagggacctggagcttt; Probe: 8. APOA2, primers: 
Fw: gagaaggtcaagagcccaga, Rv: ccttcttgatcaggggtgtc; 
Probe: 68. APOC1, primers: Fw: gccttggataagctgaagga, 
Rv: gaaatgtctctgaaaaccactcc; Probe: 47. LPL, primers: 
Fw: caggcctttgagatttctctgt, Rv: gaaggagtaggtcttatttgtggaa; 
Probe: 13. Universal Probe Library (Roche) primers 
and probes employed for mice: Ldlr, primers: Fw: 
gatggctatacctacccctcaa, Rv: tgctcatgccacatcgtc; Probe: 
64. ApoD, primers Fw: aatttccatcttgggaaatgc, Rv: 
ggatcttctcaatttcgtaccatc; Probe: 63. ApoC1, primers 
Fw: tgggaacactttggaagaca, Rv: actttgccaaatgcctctga; 
Probe: 46. ApoA2, primers Fw: tgctggtcaccatctgtagc, 
Rv: catatccggtccgtctgc; Probe: 12. ApoE, primers Fw: 
ttggtcacattgctgacagg, Rv: agcgcaggtaatcccagaa; Probe: 32. 
Lpl, Fw: tttgtgaaatgccatgacaag, Rv: cagatgctttcttctcttgtttgt; 
Probe: 47. Acat1, Fw: ggctgaactcagtaaccacaca, 
Rv: ttggcttctagccgattcc; Probe: 71. Acat2, Fw: 
attccagccataaagcaagc, Rv: tttagctattgccgcagaca; Probe: 88. 
β-ACTIN and GAPDH housekeeping assays from Applied 
Biosystems (β-ACTIN, Hs99999903_m1; GAPDH, 
Hs02758991_g1; Mm99999915_g1); showed similar 
results (all qRTPCR data presented was normalized using 
GAPDH).
Lentiviral shRNA sequences targeting HMGCR 
(TRCN0000262852 and TRCN0000262856, Sigma 
Mission Library) were cloned into TET-pLKO puro vector 
(gift from Dr. Dmitri Wiederschain [11], Addgene plasmid 
#21915). HMGCR over-expressing lentiviral plasmid 
(pLX304) was obtained from https://plasmid.med.harvard.
edu (HsCD00412328). 
Animals
All mouse experiments were carried out following 
the ethical guidelines established by the Biosafety and 
Welfare Committee at CIC bioGUNE. The procedures 
employed were carried out following the recommendations 
from AAALAC. Xenograft experiments were performed 
as previously described [12], injecting 105 cells per 
condition in two flanks per mouse (male Hsd:Athymic 
Nude-Foxn1 nu/nu). For metastasis experiment, 6x105 
cells in 200 µl were injected by tail vein [12]. When 
possible, mice were injected randomly and xenografts 
measured blindly to reduce bias due to caging. Western 
diet (SSNIFF, D12079 mod.) with high carbohydrates 
and fat (50% carbohydrates, 21% fat) was compared with 
the 4% fat of the control diet. Simvastatin was provided 
in the diets (both standard diet and western diet) at 12 
mg/kg chow. The supplied concentration of simvastatin 
in mice was equivalent to 12 mg/day in humans, which 
corresponded to low doses for anticholesterolemic 
treatment (the standard dose being 40 mg/day). 
The PtenloxP conditional knockout alleles have been 
described elsewhere [13]. Prostate epithelium specific 
deletion was effected by the Pb-Cre4. Mice were fasted 
for 6 h prior to tissue harvest in order to prevent metabolic 
alterations due to immediate food intake.
Histopathological analysis
Samples of prostate gland or lungs were fixed 
overnight in 10% neutral buffered formalin, embedded 
in paraffin and sectioned 5 µm thick and dried. Slides 
were dewaxed and re-hydrated through a series of graded 
ethanol until water and were stained with hematoxilin-
eosin (H-E). Histopathological lesions of the prostate were 
classified according to current histological criteria [14].
Detection of PC3 in lungs metastatic foci of 
immunocompromised mice in the metastasis assay 
was assessed by immunohistochemical staining of 
Vimentin (NCL-L-VIM-572, Leica biosystems) using the 
streptavidin-biotin-peroxidase complex.
Proliferation was evaluated in paraffin embedded 
prostate samples by using Ki67 antibody (MA5-14520, 
Thermo Scientific). Five fields, at least 400 cells each field 
from the AP (anterior prostate) lobe were counted. 
Immunohistochemical stainings of AR, pERK, 
pAKT and LDLR (references as in western blot analysis) 
were performed on deparaffinized prostate sections using 
the streptavidin-biotin-complex peroxidase method. 
Antigen retrieval was carried out by heating sections in 
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10 mM sodium citrate, pH 6.0. Immunodetection was 
performed with the Polink-2 HRP Plus Rabbit Detection 
System (D39-110, GBI Labs, Bothell, WA, USA) and 
slides were developed with the peroxidase substrate kit 
(SK-4105, Vector Laboratories, Burlingame, CA, USA). 
Staining score 0 to 3 was given by two independent 
investigators based on the % of stained cells and the 
intensity of the staining.
Patients
We analysed data from a prospective study 
conducted in Vall d’Hebron Research Institute [15]. To 
carry out this analysis, 2408 men were selected, after 
excluding those men who were undergoing 5-α-reductase 
inhibitors treatment and those men who had been using 
statins for less than three years. Prostate cancer (PCa) was 
detected in 848 men (35.2%), and 240 (28.3%) were high 
grade prostate cancer (HGPCa) (Gleason score > 7). The 
overall demographics and clinical characteristics of the 
men enrolled, as well as the methodological aspects have 
been previously reported [15]. 
Statistics
For patient analysis, quantitative variables were 
expressed as medians + semi-interquartile range. 
Qualitative variables were expressed as rates. Univariate 
analysis included the Chi-square test to analyse the 
association between qualitative variables and the Cochran 
test to evaluate their strength. Multivariate analysis 
using the binary logistic regression was carried out to 
examine the independent predictors of PCa risk and tumor 
aggressiveness. Odds ratios (OR) and 95% coefficient 
interval (CI) were calculated.
For in vivo studies, in the absence of normal 
distribution, a non-parametric Mann Whitney U test 
was applied for two-group comparisons. For frequency 
analysis, Chi-square test was used when there were more 
than 2 variables and Fisher F test was used for 2 variables. 
For in vitro experiments, normal distribution was assumed 
and one sample t-test was applied for one component 
comparisons with control. Error bars represent mean ± 
SEM (standard error of the mean) in vitro, and median 
with interquartile range in vivo, unless otherwise specified. 
We considered p < 0.05 to be statistically significant.
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